US biotechnology company Bicycle Therapeutics (Nasdaq: BCYC), which pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, has announced the appointment of Dr Santiago Arroyo as chief development officer, effective March 31.
In addition, Bicycle said that Jennifer Perry, has been promoted to senior vice president, commercial.
Dr Arroyo brings to Bicycle over 20 years of biopharma industry experience, leading the clinical development of therapeutics across multiple disease areas. He was previously chief medical officer at Momenta Pharmaceuticals, which was acquired by Johnson & Johnson (NYSE: JNJ) in 2020.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze